Browse all Channels
Ibio, Inc.

Ibio, Inc.
8800 HSC Pkwy ,
Bryan ,
Texas 77807
USA
  2. Companies
  3. Ibio, Inc.
  4. Products
  5. IBIO - Model 101 - Immuno Oncology ...
IBIO - Model 101 - Immuno Oncology Therapeutics

- Model 101 - Immuno Oncology Therapeutics

From

0

Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in preventing autoimmunity by keeping effector T cells [Teffs] “in-check” to prevent destruction of healthy tissues. However, around tumors, Tregs create an immunosuppressive environment and block the work of Teffs to do what they do well – kill cancer cells. So, targeting depletion of Tregs to control tumors has emerged as an area of interest in oncology over the past several years.

 

Products Details

Fortunately, Tregs express a protein, CD25, that allows them to be killed with an anti-CD25 antibody. Unfortunately, that protein is part of the interleukin-2 [IL-2] signaling, which also activates Teffs. This is what has presented a challenge; anti-CD25 antibodies can deplete Tregs, but unless they have certain characteristics, those antibodies also prevent Teffs from cancer cell killing, thereby resulting in a failure as a therapeutic to control tumor growth and metastasis.

iBio’s Approach

We signed a worldwide exclusive licensing agreement to develop and commercialize RubrYc’s therapeutic candidate, RTX-003. This monoclonal antibody [mAb] was initially developed on a traditional mammalian cell manufacturing platform but will now be advanced as IBIO-101, using iBio’s sustainable, plant-based   Expression System

This promising candidate has a novel mechanism of action that in preclinical studies has been shown to enable it to effectively bind CD25 on Tregs, but does so without blocking the IL-2 signaling pathway to Teffs. This has been the key challenge with most, but not all, other anti-CD25 mAbs.

RTX-003 stimulates anti-tumor immunity by depleting immunosuppressive Treg cells via engagement with Natural Killer [NK] Cells


More about Immuno Oncology Therapeutics

Image

IL-2 signaling in Teff cells is preserved by targe...

IL-2 signaling in Teff cells is preserved by targeting of a privileged epitope on the CD25 molecule, allowing Teffs to proliferate and control tumor growth

Development Status

Anti-tumor responses have been observed in pre-clinical models of disease using IBIO-101 as a monotherapy, as well as in combination with checkpoint inhibitors.

  • In a colon cancer xenograft model, IBIO-101 alone dose-dependently inhibited tumor growth
  • In combination with a PD1 antibody, IBIO-101 reduced tumor growth in a humanized adenocarcinoma model

Customer reviews

No reviews were found for IBIO - Model 101 - Immuno Oncology Therapeutics. Be the first to review!